BG105162A - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents

Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Info

Publication number
BG105162A
BG105162A BG105162A BG10516201A BG105162A BG 105162 A BG105162 A BG 105162A BG 105162 A BG105162 A BG 105162A BG 10516201 A BG10516201 A BG 10516201A BG 105162 A BG105162 A BG 105162A
Authority
BG
Bulgaria
Prior art keywords
coadministration
acat
mmp inhibitors
treatment
atherosclerotic lesions
Prior art date
Application number
BG105162A
Other languages
Bulgarian (bg)
English (en)
Inventor
Thomas BOCAN
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of BG105162A publication Critical patent/BG105162A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
BG105162A 1998-07-21 2001-01-17 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions BG105162A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
BG105162A true BG105162A (en) 2001-12-29

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105162A BG105162A (en) 1998-07-21 2001-01-17 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (is)
JP (1) JP2002521328A (is)
KR (1) KR20010083134A (is)
CN (1) CN1310629A (is)
AP (1) AP2001002035A0 (is)
AU (1) AU4701799A (is)
BG (1) BG105162A (is)
BR (1) BR9912296A (is)
CA (1) CA2335062A1 (is)
CZ (1) CZ2001126A3 (is)
EA (1) EA200100153A1 (is)
EE (1) EE200100046A (is)
HR (1) HRP20010055A2 (is)
HU (1) HUP0102880A3 (is)
ID (1) ID30030A (is)
IL (1) IL140982A0 (is)
IS (1) IS5809A (is)
NO (1) NO20010291L (is)
OA (1) OA11584A (is)
PL (1) PL346011A1 (is)
SK (1) SK502001A3 (is)
TR (1) TR200100205T2 (is)
WO (1) WO2000004892A2 (is)
YU (1) YU3501A (is)
ZA (1) ZA200100294B (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003513909A (ja) * 1999-11-05 2003-04-15 ワーナー−ランバート・カンパニー Ａｃａｔ阻害剤によるプラーク破裂の予防
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
EP1237862A1 (en) * 1999-12-17 2002-09-11 Versicor, Inc. Succinate compounds, compositions and methods of use and preparation
AU8254101A (en) * 2000-09-01 2002-03-22 Sankyo Co Medicinal compositions
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
NZ536116A (en) * 2002-04-03 2007-01-26 Topotarget Uk Ltd Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
CA2492035A1 (en) * 2002-07-11 2004-01-15 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
WO2016113713A1 (en) * 2015-01-15 2016-07-21 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
CN1192140A (zh) * 1995-08-04 1998-09-02 沃尼尔·朗伯公司 氨基磺酸衍生物、酰基磺酰氨或磺酰基氨基甲酸酯在制备降低脂蛋白水平的药物中的用途
CZ294063B6 (cs) * 1996-05-17 2004-09-15 Warner-Lambert Company Bifenylsulfonamid, jeho použití a farmaceutický prostředek s jeho obsahem
NZ333063A (en) * 1996-09-04 2000-12-22 Warner Lambert Co Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
ZA200100294B (en) 2002-01-10
KR20010083134A (ko) 2001-08-31
NO20010291D0 (no) 2001-01-18
CZ2001126A3 (cs) 2002-01-16
CN1310629A (zh) 2001-08-29
IS5809A (is) 2001-01-12
EP1098662A2 (en) 2001-05-16
EE200100046A (et) 2002-06-17
AU4701799A (en) 2000-02-14
HUP0102880A2 (en) 2002-06-29
PL346011A1 (en) 2002-01-14
SK502001A3 (en) 2002-06-04
AP2001002035A0 (en) 2001-03-31
JP2002521328A (ja) 2002-07-16
CA2335062A1 (en) 2000-02-03
WO2000004892A3 (en) 2000-05-18
ID30030A (id) 2001-11-01
OA11584A (en) 2004-07-20
EA200100153A1 (ru) 2001-08-27
TR200100205T2 (tr) 2001-05-21
BR9912296A (pt) 2001-04-17
IL140982A0 (en) 2002-02-10
HUP0102880A3 (en) 2002-11-28
NO20010291L (no) 2001-01-18
YU3501A (sh) 2005-06-10
HRP20010055A2 (en) 2002-04-30
WO2000004892A2 (en) 2000-02-03

Similar Documents

Publication Publication Date Title
YU3501A (sh) Zajedničko ordiniranje inhibitora acat i mmp za tretman oštećenja od ateroskleroze
WO2000038730A3 (en) Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
IL137465A0 (en) Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
EP1319404A3 (de) Mittel zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
IL128080A0 (en) Thiol sulfonamide metalloprotease inhibitors
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
WO2002003978A3 (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
GB9804886D0 (en) Therapeutic combination
HUP0103424A3 (en) Use of eletriptan for the prevention of migraine recurrence
FR2744621B1 (fr) Determination des tunnels femoral et tibial pour la reconstruction isometrique du ligament croise anterieur
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου
WO1999002565A3 (de) Mittel zur behandlung und/oder prophylaxe von mikrozirkulationsstörungen
EP0755679A3 (en) Use of Amtolmetin Guacil as an anti-inflammatory agent, which also inhibits gastric secretion
CA2322967A1 (en) Prophylactic, therapeutic agent for osteoporosis
IT1302813B1 (it) Dispositivo per la riduzione diretta di ossidi di ferroe relativo procedimento
GB9824875D0 (en) Use of an agent for the prevention of gum disease
ID26666A (id) Penggunaan agen untuk pencegahan penyakit gusi
IL152989A0 (en) Use of riluzole or its salts for preventing and treating ?noleukodystrophy
EP1115687A4 (en) 5,6-DIHYDRONAPHTHALENYL DERIVATIVES WITH RETINOID-LIKE ACTIVITY
TW374520U (en) Increasing and deducting structure for the metal guide foot of the computer line terminals
GB9810521D0 (en) Use of an agent in the manufacture of a medicament
SI1100499T1 (en) Use of eletriptan for the prevention of migraine recurrence
KR960014949U (ko) 브레이크 라이닝의 마모감지장치
ZA97168B (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment of prophylaxis of prostatic carcinoma